JAMA examines black market for unapproved retatrutide and zenagamtide
The Medical News piece looks at why buyers turn to online sellers of the two investigational incretin drugs and what risks they take on.
MH
By Maren Holt · Senior Reporter, GLP-1
Oct 8 20:00 ETSource: JAMA
The wire
- 01A JAMA Medical News article by Rubin and colleagues describes the growing online black market in retatrutide and zenagamtide, two GLP-1-class drugs that are not approved for any use.
- 02Clinicians and pharmacists are increasingly fielding questions from patients self-sourcing investigational incretins that have no approved label, dosing or quality assurance.
- 03The piece is journalism rather than original data, so it characterizes risk and motivation without quantifying harm from specific products or sellers.
From the source
Read at pubmed.ncbi.nlm.nih.govUnapproved GLP-1 Drugs Retatrutide and Zenagamtide Sold Online Are No Bargain
JAMA · 2026 Oct 9 · Rubin R et al.
Source URL https://pubmed.ncbi.nlm.nih.gov/42853576/
